Query1.xls

NIHR Delivery Q2
Recruitment
Recruitment
Research Title
REC Reference
Target Date
Project Status
Target Met
ARRIVE - Aspirin to Reduce Risk of Initial Vascular Events - A randomised, double-blind, placebo-controlled, multicenter, parallel group study to assess the efficacy (reduction of cardiovascular disease events) and safety of 100mg enteric-coated acetylsal ALTITUDE - A randomised double-blind placebo-controlled parallel group study to determine whether, in patients with type II diabetes at high-risk of cardiovascular and renal events, aliskerin, on top of conventional treatment, reduces cardiovascular and r A double-blind, randomised, stratified, multi-center trial evaluating conventional and high dose oseltamivir in the treatment of immunocompromised patients with influenza A phase IIIb, open, multi centre gynaecological extension study for follow-up of a subset of 580299/008 study subjects who were either cervical cytology negative and oncogenic HPV positive or pregnant at their final 580299/008 study visit (visit 10 at mo A phase 3 Observer blind Randomized, Multi-center, Controlled study to evaluate the effect of Novartis Vaccines Meningococcal B recombinant and MenACWY Conjugate vaccines on Nasopharyngeal Carriage of N. Meningitidis in Young Adults HGT-SAN-055 - A Phase I/II Safety, Tolerability, Ascending Dose and Dose Frequency Study of Recombinant Human Heparan N-sulfatase(rhHNS) Intrathecal Administration via an Intrathecal Drug Delivery Device in Patients With Sanfilippo Syndrome Type A A phase IIIb, open, multi-centre gynaecological extension study for the follow-up of a subset of HPV-015 study subjects OSKIRA-X - A Long-term Extension Study to Assess the Safety and Efficacy of Fostamatinib Disodium (FosD) in the Treatment of Rheumatoid Arthritis Trial consisting of an 8-week double-blind placebo-controlled part to evaluate efficacy, safety, tolerability and pharmacokinetics of prucalopride in paediatric subjects with functional constipation, aged 6 months to <18 years, followed by a 16-week open- A 6-month, multicentre, randomised, double-masked phase IIIb study comparing the efficacy and safety of Lucentis (ranibizumab) intravitreal injections versus Ozurdex (dexamethasone) intravitreal implant in patients with visual impairment due to macular A 6-month multicenter, randomized, double-masked phase IIIb-study comparing the efficacy and safety of Lucentis (Ranibizumab) intravitreal injections versus Ozurdex (Dexamethasone) intravitreal implant in patients with visual impairment due to macular NIHR Delivery Q2
Recruitment
Recruitment
Research Title
REC Reference
Target Date
Project Status
Target Met
A Phase 3, Prospective, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Intact Parathyroid Hormone Levels in Pediatric Subjects Ages 10 to 16 A Phase II, Open-Label, Multi-Center Study to Compare the Pharmacokinetics of Tacrolimus in Stable Paediatric Allograft Recipients Converted from a Prograf-Based Immunosuppressive Regimen to a Tacrolimus Prolonged Release, Advagraf-Based Immunosuppressive A multi-centre, randomised, double-blind, placebo-controlled, single dose, dose escalation trial investigating safety, pharmacokinetics and pharmacodynamics of NNC 0172-0000-2021 administered intravenously and subcutaneously to healthy male RETAIN - A 2 year randomized, single-masked, multicentre, controlled phase IIIb trial assessing the Efficacy and safety of 0.5mg ranibizumab in two ?treat and extend? treatment algorithms vs. 0.5 mg ranibizumab as needed in patients with macular edema PME/ Master Study of the Lumax 740 ICD family A randomised partially-blind, placebo-controlled, pilot, dose-ranging study to assess the effect of cannabidiol (CBD) on liver fat levels in subjects with fatty liver disease ST10-021-301: A prospective, multicentre, randomised, double-blind, placebo controlled study with oral ST10-021 for the treatment of iron deficiency anaemia in subjects with quiescent ulcerative colitis where oral ferrous preparations have failed or canno BO20924: Open-label, multi-center, randomized, two stage adaptive design study of the combination of bevacizumab with standard chemotherapy in minor patients with metastatic rhabdomyosarcoma, non-rhabdomyosarcoma soft-tissue sarcoma or Ewing?s sarcoma/sof HGT-SAN-067 - An Open-Label Extension of Study HGT-SAN-055 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Administration of rhHNS in Patients with Sanfilippo Syndrome Type A (MPS IIIA) Prospective, Multicenter, Single Arm Feasibility and Safety Study of the Endologix Fenestrated Stent Graft System for the Endovascular Repair of Juxtarenal/Pararenal A 26 week, Multinational, Multicentre, Open Labelled, Randomised, Parallel, Efficacy and Safety Comparison of Insulin Degludec and Insulin Detemir in children and adolescents 1 to less than 18 years with type 1 Diabetes Mellitus on a basal bolus regimen w NIHR Delivery Q2
Recruitment
Recruitment
Research Title
REC Reference
Target Date
Project Status
Target Met
An Open-Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination with Bortezomib in Subjects with Relapsed and/or Refractory Multiple Myeloma MOR-004 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multinational Clinical Study to Evaluate the Efficacy and Safety of 2.0 mg/kg/week and 2.0 mg/kg/every other week BMN 110 in Patients with Mucopolysaccharidosis IVA (Morquio A multicenter, open-label study to evaluate the clinical and economic benefits of low voltage stereotactic radiotherapy in subjects with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) A UK open-label, multicentre, exploratory phase 11 study of INC424 for patients with primary myelofibrosis (PMF) or post polycythaemia myelofibrosis (PPV MF) or postessential thrombocythaemia myelofibrosis (PET-MF) BAX326 (RECOMBINANT FACTOR IX): A PHASE 2/3 PROSPECTIVE, UNCONTROLLED, MULTICENTER STUDY EVALUATING PHARMACOKINETICS, EFFICACY, SAFETY, AND IMMUNOGENICITY IN PREVIOUSLY TREATED PEDIATRIC PATIENTS WITH SEVERE (FIX LEVEL < 1%) OR MODERATELY A Randomised, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects with Moderately-to-Severely Active Crohn?s Disease The Ovation? Abdominal Stent Graft System Post-Market Study (?OVATION Post-Market Study?) PEGASUS - A Randomised, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events with Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients with Histor A three part, staggered cohort, open-label and double blind, randomized, placebo controlled study to investigate the efficacy, safety, tolerability and pharmacokinetics of eltrombopag, a thrombopoietin receptor agonist, in previously treated pediatric pat Taste and palatability of Orfadin suspension. An open, non-controlled 3-day study in pediatric patients with hereditary tyrosinemia type 1 treated with Orfadin Ingenol Mebutate Gel, 0.015% Repeat Use for AKs on Face and Scalp A phase III, observer-blind, randomized, multi-country, non-influenza vaccine comparator-controlled study to demonstrate the efficacy of GlaxoSmithKline Biologicals? quadrivalent seasonal influenza candidate vaccine GSK2321138A (FLU Ferumoxytol for Iron Deficiency Anaemia in Nondialysisdependent CKD NIHR Delivery Q2
Recruitment
Recruitment
Research Title
REC Reference
Target Date
Project Status
Target Met
Ferumoxytol for Iron Deficiency Anaemia in Dialysis-dependent CKD OSKIRA 4 - A Phase IIB, MultiCentre, Randomised, Double Blind, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of Fostamatinib Disodium Monotherapy Compared with Adalimumab Monotherapy in Patients with ActiveRheumatoid Arthritis A randomized, doubleblind, placebo controlled study to assess the efficacy, safety and tolerability of LCQ908 in subjects with Familial Chylomicronemia Syndrome.
A Phase 3 clinical study to determine the safety and efficacy of rVWF:rFVIII and rVWF in the treatment and prevention of bleeding episodes in subjects diagnosed with von Willebrand disease A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anaceptrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients wit TRAPID-AMI study - High sensitivity cardiac Troponin T assay for RAPID rule-out of Acute Myocardial Infarction - A multicenter, prospective, observational study validating an algorithm for early rule-out of acute myocardial infarction in undifferentiated MOR-007 - A Phase 2, Open-label, Multinational Clinical Study to Evaluate the Safety and Efficacy of BMN 110 in Pediatric Patients Less Than 5 Years of Age with Mucopolysaccharidosis IVA (Morquio A Syndrome) Argus? II Retinal Stimulation System Feasibility Study FER-CKD-01 An open-label, multicentre, randomized, 3-arm study to investigate the comparative efficacy and safety of intravenous ferric carboxymaltose (Ferinject? high- and low-dosage regimens) versus oral iron for the treatment of iron deficiency anaemi A double blind, placebo-controlled, randomized Phase 2 study of BHQ880, an anti-Dickkopf1 (DKK1) monoclonal antibody (mAB), in patients with untreated multiple myeloma and renal insufficiency Evaluation of the effects of agomelatine (25mg and 50mg) and escitalopram 20mg during 8 weeks on emotional blunting, emotional processing and motivation in healthy BAX326 (recombitant factor IX): Evaluation of safety, immunogenicity, and hemostatic efficacy in previously treated patients with sever (FIX level less than 1%) or moderately severe (FIX level less than or equal to 2%) hemophilia B - A continuation study NIHR Delivery Q2
Recruitment
Recruitment
Research Title
REC Reference
Target Date
Project Status
Target Met
A 52 week Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Maintenance of Remission in Subjects with Crohn?s Disease An Open-Label Extension Study of the Safety and Efficacy of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anaemia in Paediatric Subjects with Chronic Kidney Disease (CKD) A Comparative Single-Dose Pharmacokinetic and Safety Study of TAK-491 Between Infants, Children, and Adolescents With Hypertension and Healthy Adults UNITI 2 - A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severely Active Crohn?s Disease UNITI 1 - A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severely Active Crohn?s Disease Who Have Failed or Are A double blind, double dummy, randomised, multicentre study to assess the tolerability and efficacy profile of vildagliptin compared to gliclazide as dual therapy with metformin in Muslim patients with type 2 diabetes fasting during Ramadan A phase 3, randomized, double-blind, placebo-controlled, parallel-group study to asses the safety and effiacy of two different regimens of Mipomersen in patients with Familial Hypercholesterolemia and inadequately controlled low-density-lipoprotein choles Ofatumumab versus Rituximab Salvage Chemoimmunotherapy followed by ASCT in PROGRESSION - A Long-term, Open-label, Noncomparative Study to Evaluate the Safety and Efficacy of a Modigraf? Based Immunosuppression Regimen in Paediatric Solid Allograft Recipients.
A Randomized, Double-blind, Multiple Dose Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects with Moderate to Severe Ulcerative Colitis Study AMNA2120 study - A multi-center, open-label, pharmacokinetic study of oral nilotinib in pediatric patients with Gleevec? (imatinib)-resistant/intolerant Ph+ CML chronic phase (CP) or accelerated phase (AP) or with refractory/relapsed Ph+ ALL An Ascending Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of PF 05280602, a Recombinant Factor VIIA Variant (813D), in Adult Haemophilia A and B Subjects with or without Inhibitors.
Performance evaluation of the novel Abbott i-Stat beta-HCG cartridge NIHR Delivery Q2
Recruitment
Recruitment
Research Title
REC Reference
Target Date
Project Status
Target Met
A phase 2 multi-centre, historically-controlled study of Dasatinib added to standard chemotherapy in paediatric patients with newly diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukaemia (Ph+ ALL) A Phase II, Parallel Group, Randomized, Multicentre, Open Label Study to Compare the Pharmacokinetics of Tacrolimus in De Novo Pediatric Allograft Recipients Treated with an Advagraf? or Prograf? Based Immunosuppressive Regimen, Including a Long-Term Foll A prospective, nonrandomised study to evaluate the safety and efficacy of the market released Medtronic Attain Performa Quadripolar left ventricular leads (Models 4298,4398, and 4598) during and after the implant procedure, in patients indicated for a car Intervention study to assess the effect of daily consumption of a lutein-enriched egg beverage on maintenance ofvisual function in subjects with early signs of Age-related Macular Degeneration The Sideguard Coronary Sidebranch Registry - A post market registry to observe the clinical outcomes of the Bare Metal Sideguard? Coronary Sidebranch stent in de novo Bifurcation Lesions of Native Coronary Arteries A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients with Heterozygous Familial Hypercholesterolemia Not Adequately Controlled with Their Lipid-ModifyingTherapy A phase II open-label, randomized, multi-centre comparative study of bevacizumab-based therapy in paediatric patients with newly diagnosed supratentorial high-grade glioma Stability, long term survival and tolerability of a novel Baha? implant system - a A post-market study to evaluate the expedium memory spine system in the treatment of PRIZE - A 3-Phase Study to Evaluate Sustained Remission and Productivity Outcomes in Subjects With Early Rheumatoid Arthritis Initiated on Treatment With Etanercept Plus A Multicenter, Prospective, Observational, Non-Interventional Cohort Study Evaluating On-Treatment Predictors of Response in Subjects with HBeAg positive or HBeAg negative Chronic Hepatitis B Receiving Therapy with PEGASYS? (Peginterferon alfa-2a 40KD) INFUSE AMI - A 2x2 Factorial, Randomized, Multicenter, Single-Blind Evaluation of Intracoronary Abciximab Infusion and Aspiration Thrombectomy in Patients Undergoing Percutaneous Coronary Intervention for Anterior ST-Segment Elevation Myocardial NIHR Delivery Q2
Recruitment
Recruitment
Research Title
REC Reference
Target Date
Project Status
Target Met
MOR-100 - A Multicenter, Multinational, Open-Label Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome) A Golimumab Phase 3b, Multicenter, Switch Assessment of Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment with Etanercept (ENBREL) or Adalimumab (HUMIRA) PARADIGM-HF - A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fract PREVENT - Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE? (infliximab) and Placebo in the Prevention of Recurrence in Crohn?s Disease Patients Undergoing Surgical Resection Who Are at an Increased Risk of R A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial on Safety of Monthly Replacement Therapy with Recombinant Factor XIII (rFXIII) in Subjects with Congenital Factor XIII Deficiency SIGNIFY - Effects of Ivabradine in Patients with Stable Coronary Artery Disease without Clinical Heart Failure. A Randomised, Double-Blind, Placebo-Controlled, International A Double-Blind, Placebo-Controlled Study in Huntington?s Disease Patients to Determine the Safety and Tolerability of SEN0014196 Modifying Orphan Disease Evaluation (MODE) Study: A multicenter, open-label study of the effects of CER-001 on plaque volume in subjects with Homozygous Familial Hypercholesterolemia An open label, multicentre, dose escalation study to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of SBC-102 in children with growth failure due to lysosomal acid lipase deficiency A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX140-B in Diabetic Nephropathy ST10-021-302 - A prospective, multicentre, randomised, double-blind, placebo controlled study with oral ST10-021 for the treatment of iron deficiency anaemia in subjects with quiescent Crohn?s Disease where oral ferrous preparations have failed or cannot HGT-HIT-072 - A Cerebrospinal Fluid Collection Study in Paediatric and Adult Patients with Hunter Syndrome A phase II, randomized double-blind study of efficacy and safety of two dose levels of LDE225 in patients with locally advanced or metastatic basal cell carcinoma - BOLT NIHR Delivery Q2
Recruitment
Recruitment
Research Title
REC Reference
Target Date
Project Status
Target Met
An open-label extension study of (canakinumab) ACZ885 in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestations.
Interventional randomised, double-blind, parallel-group, placebo-controlled, exploratory study investigating the effects of Lu AA21004 on cognition and BOLD fMRI signals in subjects remitted from depression and controls A phase III open-label randomised study, to evaluate the immunogenicity and safety of the concomitant administration of V419 (PR5I) given at 2, 3 and 4 months of age with two types of meningococcal serogroup C conjugate (MCC) vaccines given at 3 and 4 mon A Phase 2b dose ranging study to evaluate the efficacy and safety of sifalimumab in adult subjects with systemic lupus erythematosus Protocol OSI-774-205 - A Randomized, Phase 2 Study of Single-agent Erlotinib versus Oral Etoposide in Patients with Recurrent or Refractory Pediatric Ependymoma First year growth response associated genetic markers validation Phase IV open-label study in Growth Hormone Deficient and Turner Syndrome prepubertal children : the PREDICT Pharmacogenetics Validation Study Double-blind, randomized, vehicle- and comparator-controlled, multi-center trial to evaluate the efficacy and safety of LAS41007 in the treatment of actinic keratosis VALOR - Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (AML) BEL116472 - A 2 year mechanistic study of belimumab in Idiopathic Membranous Glomerulonephropathy A two-part, double-blind, randomised, placebo-controlled and open-label study to investigate the efficacy, safety and tolerability of eltrombopag, a thrombopoietin receptor agonist, in pediatric patients with previously treated chronic immune (idiopathic) A Phase 3,Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients with Primary Biliary Cirrhosis A Randomized, Double-Blind, Placebo-Controlled, Phase 2 study to evaluate the Safety and Efficacy of CCX168 in Subjects with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Renal Vasculitis on Background Cyclophosphamide Treatment MOR008 - A Randomised, Double-Blind, Pilot Study of the Safety and Physiological Effects of Two Does of BMN-110 in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome) An open-label, multi-center, ascending dose study of the tolerability and safety of recombinant human acid sphingomyelinase (rhASM) in patients with acid sphingomyelinase deficiency (ASMD) NIHR Delivery Q2
Recruitment
Recruitment
Research Title
REC Reference
Target Date
Project Status
Target Met
Long-term safety and tolerability of SAR236553 (REGN727) in high cardiovascular risk patients with hypercholesterolemia not adequately controlled with their lipid modifying therapy: a randomized, double-blind, placebocontrolled study (ELIXA): EFC11319 - A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate cardiovascular outcomes during treatment with lixisenatide in type 2 diabetic patients after an Acute Coronary Syndrome A randomized, double blind, 12-week, parallel group, placebo controlles study of the efficacy and safety of R04917523 in patients with Fragile X Syndrome An Open-Label, Single-Dose Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Cinacalcet HCl in Pediatric Subjects Aged 28 Days to <6 Years with Chronic Kidney Disease Receiving Dialysis An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects with Crohn's Disease A phase 3, multicentre, randomized, open-label study of azacitidine (Vidaza) versus conventional care regimens for the treatment of older subjects with newly diagnosed A Phase III international, randomized, double-blind, double-dummy study to evaluate the efficacy and safety of 300mg or 600mg of intravenous zanamivir twice daily compared to 75mg of oral oseltamivir twice daily in the treatment of hospitalized adults and Speculus 223 Proof of concept clinical investigation CLINICAL INVESTIGATION TO ASSESS THE SAFETY AND EFFICACY OF THE TENDRIL MRI? LEADS, AS A PART OFACCENT MRI? SYSTEM, IN PATIENTS WITH STANDARD BRADYCARDIA PACING INDICATION.
OPTION - A Multicentre, Open-Label, Pharmacokinetic Study of Modigraf? (Tacrolimus granules) in de novo Paediatric Allograft Recipients.
Randomised, phase IV, placebo-controlled, comparative study to evaluate the efficacy and safety of tapering methotrexate (MTX) dosage versus maintaining the dosage in patients with severe active rheumatoid arthritis (RA) who have demonstrated an inadequat A phase III, randomised, observer blind,placebo controlled, multicentre, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of GSK Biologicals' herpes zoster gE/AS01b candidate vaccine when administered intramuscularly on a two Measuring Ammonia in Breath of children with Urea Cycle or Organic Acid Metabolic Disorders Safety and efficacy evaluation of Recombinant Factor XIII for Prevention of Bleeding in Paediatric Patients with FXIII A-subunit Congenital Deficiency.
NIHR Delivery Q2
Recruitment
Recruitment
Research Title
REC Reference
Target Date
Project Status
Target Met
MOR-005 - A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome) IMUNITI - A Phase 3, Multicenter, Randomized, Placebo-controlled, Parallel-Group, Double-blind Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects with Moderately to Severely Active Crohn?s Disease PROTECT - Patient Related OuTcomes with Endeavor versus Cypher stenting Trial - A Prospective, Multicenter, Randomized, Two-Arm, Open-Label Trial A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite Anti-TNF Therapy 12/YH/0446 Pharmacokinetic and safety study of human coagulation factor XI (HEMOLEVEN) in patients with severe inherited factor XI deficiency AKPA 3-001: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy Effects of ART-123 on Subjects with Severe Sepsis and Coagulopathy A Randomized, DoubleBlind, PlaceboControlled, ParallelGroup Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome Openlabel, singlearm, phase IV, multicentre trial to explore the immunogenicity of the liquid formulation of Saizen? in subjects with growth hormone deficiency (GHD) of adult onset A MultiCentre,double blind, randomised, placebocontrolled, parallelgroup, Phase 3 study to evaluate the effects of macitentan on exercise capacity in subjects with Eisenmenger Syndrome.
PROTEAse inhibitor (DRV/rtv) in mono- or triple therapy in suppressed HIV-1 infected subjects.
A Doubleblind, Randomized, Placebo and Ezetimibe Controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDLC in Combination With Statin Therapy in Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia 12/NW/0672 A Doubleblind, Randomized, Placebocontrolled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDLC in Subjects with Heterozygous Familial Hypercholesterolemia A Randomised, Doubleblind, Active Treatment Study to Induce Clinical Response and/or Remission with GSK1605786A in Subjects with Moderately to Severely Active Crohn?s Disease NIHR Delivery Q2
Recruitment
Recruitment
Research Title
REC Reference
Target Date
Project Status
Target Met
BAX 326 (recombitant Factor IX): A phase 3 prospective, multi-centre, study evaluating efficacy and safety in previously treated patients with severe (FIX level < 1%) or moderately severe (FIX level = 2%) hemophilia B undergoing surgical or other invasive 11/LO/1238 A 12-week randomized, open-label, active comparator period followed by a 12-week safety extension period to evaluate the safety and efficacy of Fesoterodine in subjects aged 6 to 16 years and >25 kg with symptoms of detrusor overactivity associated with a 12/NW/0694 Efficacy and safety of Liraglutide in combination with metformin versus metformin monotherapy on glycaemic control in children and adolescents with type 2 diabetes. A 14-week double-blind, randomised, parallel group, placebo controlled multi-centre trial A Phase 2, Open-label, Multinational Study to Evaluate the Efficacy and Safety of BMN 110 in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome) Who Have Limited Ambulation GIRAFFE - A multicenter, open-label, single ascending dose study to evaluate pharmacokinetics, safety and tolerability of solifenacin succinate suspension in pediatric patients aged 5 to 17 years (inclusive) with overactive bladder (OAB) CMV: ASPECT - Cytomegalovirus: Alternate Donor Study of Pre-Emptive Cellular Therapy - A prospective phase II study to investigate the efficacy and safety of pre-emptive Cytomegalovirus Adoptive Cellular Therapy in patients receiving allogeneic haematopoi A five-year registry study of Humira (Adalimumab) in subjects with moderately to severely active Crohns Disease Assurity?+/Assurity?/Endurity? SR/DR and Allure? CRT-P New Technology Assessment A Multicentre, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination with Metformin IR or Metformin XR in Paediatric Patients with Type 2 Diabetes who have Inadequate Glycaemic Co GENA-03 - PROSPECTIVE CLINICAL STUDY IN CHILDREN WITH SEVERE HAEMOPHILIA A TO INVESTIGATE CLINICAL EFFICACY, IMMUNOGENICITY, PHARMACOKINETICS, AND SAFETY OF HUMAN-CL RHFVIII A study comparing the effectiveness between Otamixaban and Unfractionated Heparin with Eptifibatide in patients with an Acute Coronary Syndrome scheduled for early A Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of 700 ?g Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) to Ranibizumab in Patients With Diabetic Macular Edema NIHR Delivery Q2
Recruitment
Recruitment
Research Title
REC Reference
Target Date
Project Status
Target Met
Determination of Safety, Efficacy, and Pharmacokinetics of GreenGene? F in Previously Treated Patients 12 years of age or older Diagnosed with Severe Hemophilia A A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects A phase 3, multicenter, randomized, doubleblind study to compare the efficacy and safety of oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with red blood cell transfusion-dependent anemia and thrombocytopen 13/ES/0005 The IN.PACT Global Clinical Study for the Treatment of Comprehensive Superficial Femoral and/or Popliteal Artery Lesions Using the IN.PACT Admiral? Drug-Eluting An 8week phase I/II, multicenter, randomized, doublemasked, vehicle controlled parallel group study with a 48 or 56 week followup period to evaluate the safety and efficacy of two doses (10 ?g/ml and 20 ?g/ml) of recombinant human nerve growth factor eye A Phase 2/3, Multi-Center, Open Label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (BAX 855) Administered for Prophylaxis and Treatment of Bleeding in Previously Treated Patients with Severe Hemophilia A A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients with Sickle Cell Disease A Randomized, Double-Blind, Placebo-Controlled Parallel Study with an Open-Label Extension to Assess the Impact of Testosterone Solution on Total Testosterone, Sex Drive and Energy in Hypogonadal Men ENDEAVOR - A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients with Relapsed Multiple Myeloma Risk of Squamous Cell Carcinoma on Skin Areas Treated with Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5% A Phase 3/4, MultiCentre, Randomized, Double Blind, Placebo Controlled, 52 Week GLOBAL LEADERS: Comparative effectiveness of 1 month of ticagrelor plus aspirin followed by ticagrelor monotherapy versus a currentday intensive dual antiplatelet therapy in allcomers patients undergoing percutaneous coronary intervention with bivalirudin A multi-center, phase III, non-controlled, open-label trial to evaluate the pharmacokinetics, safety, and efficacy of BAY 94-9027 for prophylaxis and treatment of bleeding in previously treated children (age <12 years) with severe hemophilia A NIHR Delivery Q2
Recruitment
Recruitment
Research Title
REC Reference
Target Date
Project Status
Target Met
A PlaceboControlled, Multicenter, Double Blind, Randomized, Pharmacokinetic and Pharmacodynamic Trial of IDN6556 in Subjects with AcuteonChronic Liver Failure A Multicenter, Openlabel Study to Assess the Longterm Safety, Tolerability, and Efficacy of AMG 145 on LDLC in Subjects With Severe Familial Hypercholesterolemia An OpenLabel Phase 1/2 Study to Assess the Safety, Efficacy and Dose of UX003 rhGUS Enzyme Replacement Therapy in Patients with MPS 7 A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5 mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial growth factor The Safety and Effectiveness of the Hydus Aqueous Implant for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery, A Prospective, Multicenter, Randomized, Controlled Clinical Trial Hydrus 4 Study An open label, pilot clinical investigation of Electrical Pharyngeal Stimulation for the treatment of chronic dysphagia A Randomised, Doubleblind, Active Treatment Study to Induce Clinical Response and/or Remission with GSK1605786A in Subjects with Moderately to Severely Active Crohn?s Disease

Source: http://www.trafford.nhs.uk/media/784485/nihr_delivery_q2.pdf